Cover Image
市場調查報告書

糖尿病管理技術 2017-2027年:預測、企業、機會

Technologies for Diabetes Management 2017-2027: Forecasts, Players, Opportunities

出版商 IDTechEx Ltd. 商品編碼 482400
出版日期 內容資訊 英文 232 Slides
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病管理技術 2017-2027年:預測、企業、機會 Technologies for Diabetes Management 2017-2027: Forecasts, Players, Opportunities
出版日期: 2017年07月31日 內容資訊: 英文 232 Slides
簡介

預估人工胰臟技術市場規模將於2027年超過65億美元。

本報告調查糖尿病管理技術主要7大領域,彙整相關市場部門10年預測、主要企業簡介、以及主要國家監管情況分析等情報。

第1章 摘要整理

第2章 簡介:糖尿病

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病對母親及嬰兒的威脅
  • 1型糖尿病與2型糖尿病之差異
  • 全球糖尿病數據
  • 糖尿病治療成本:按地區
  • 糖尿病治療成本高
  • 糖尿病副作用佔糖尿病治療成本的90%
  • 糖尿病病患數增加
  • 糖尿病技術技術及功能

第3章 市場預測

  • 預測假設
  • 市場預測:1型糖尿病患者的血糖監測主要方法
  • 市場預測:拋棄式試紙,按收入
  • 市場預測:拋棄式試紙,按數量
  • 市場預測:葡萄糖測量儀,按收入
  • 市場預測:葡萄糖測量儀,按數量
  • 市場預測:穿戴式葡萄糖感測器,按收入
  • 市場預測:穿戴式葡萄糖感測器,按數量
  • 市場預測:可重複使用胰島素筆針裝置,按數量
  • 智慧筆針裝置的龐大市場成長預測
  • 市場預測:胰島素幫浦,按收入
  • 市場預測:胰島素幫浦,按數量
  • 胰島素幫浦內感測器

第4章 葡萄糖監測感測器

  • 葡萄糖監測
  • 葡萄糖監測歷史
  • 葡萄糖監測試紙機制
  • 葡萄糖監測化驗的開發
  • 葡萄糖測量儀的試紙監測
  • 試紙製造商
  • 血糖監測儀的進步
  • 血糖監測商業模式
  • 血糖監測儀製造商
  • 電極沉積:網印 vs. 濺鍍,其他

第5章 血糖之外的測量

  • 血液之外的測量
  • 汗液葡萄糖測量
  • 眼淚葡萄糖測量
  • 間隙液葡萄糖測量
  • 唾液葡萄糖測量
  • 呼氣葡萄糖測量
  • 尿液葡萄糖測量
  • 各種葡萄糖採樣
  • 定性血糖監測
  • 持續血糖測量 (CGM) ,其他

第6章 酮監測感測器

  • 嚴重缺乏胰島素可能導致糖尿病酮酸症
  • Ketostix 為一個有歷史具效用的DKA測量法
  • 電化學感測器是酮監測的準確方法
  • 葡萄糖及酮試紙比較
  • 酮監測

第7章 胰島素筆針感測器

  • 胰島素筆針仍是病患主要輸藥方法
  • 胰島素筆針解剖
  • 忘記服藥可能致命
  • 智慧胰島素輸藥裝置製造商
  • 首次智慧筆針進入市售
  • 智慧筆針平台防止忘記投藥
  • 傳統胰島素筆針產業投資組合多樣化
  • Bluetooth連接筆針預計將於美國販售
  • 適用拋棄式胰島素筆針原則
  • 是否有空間給新的胰島素筆針製造商?

第8章 胰島素幫浦:朝向人工胰臟

  • 胰島素幫浦提供自動輸藥系統
  • 目前可利用的胰島素幫浦
  • 邁向完全自動化胰島素輸藥
  • 胰島素幫浦分析
  • 幫浦內感測器功能
  • 胰島素幫浦技術Roadmap
  • 對自動糖尿病管理的胰島素幫浦的侵駭
  • 閉環系統來臨
  • 模組系統實現人工胰臟
  • 2型糖尿病的拋棄式胰島素幫浦,其他

第9章 副作用感測器

  • 副作用的治療佔糖尿病成本的80%
  • 糖尿病足潰瘍
  • 可檢測腳問題的壓力、衝擊感測器
  • 糖尿病病患的鞋類基本要求
  • 糖尿病病患的鞋內底
  • Sensoria:糖尿病病患的襪子
  • 糖尿病性神經疾病
  • 神經疾病的光學測量
  • 作為神經疾病生物標記的汗腺機能
  • 評估神經疾病的步態測量

第10章 早期診斷感測器

  • 糖尿病診斷並非快速過程
  • 遠端葡萄糖耐受試驗是可能的
  • 大腸桿菌於糖存在之下會變色
  • 嬰兒診斷的光學感測器

第11章 糖尿病醫療設備規範及可用性

  • 奧地利
  • 加拿大
  • 法國
  • 德國
  • 愛爾蘭
  • 荷蘭
  • 瑞士
  • 英國
  • 美國

第12章 企業簡介

  • Companion Medical
  • Dexcom
  • Dropsens
  • Emperra
  • Glysens
  • Google-Verily
  • GSI
  • GSK Medical
  • Medtronic
  • Nanoflex
  • PKVitality
  • Sensoria

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

"The market for artificial pancreas technologies will exceed $6.5 billion by 2027."

This report from IDTechEx covers mature, growing and emerging fields in diabetes technology, researched through primary interviews with companies, physicians and diabetic individuals to establish how the technological roadmap for diabetes management will develop over the next decade.

Historically glucose levels have been monitored using disposable biosensors, whereby a drop of blood is placed on to a sensor and an associated reader provides the result. While the glucose test strip industry produces billions of single use sensors a year, cuts to medical budgets are driving profitability down. Current invasive methods of glucose monitoring result in low patient compliance, leading to poor glucose control and the associated long term health implications. These factors have led both start-ups and established players in the field to develop novel glucose sensing platforms based on alternative sampling sites and detection methods. Whilst many of these technologies will not be able to precisely replicate the accuracy of blood glucose measurements, some are making progress towards this goal and are achieving regulatory approval to commercialise products in to this emerging market.

Advancements in diabetes care are not limited to glucose monitoring, novel insulin delivery platforms provide another area of growth for the industry, with wearable insulin pumps now widely available. Such devices contain a range of sensors to that enable the safe and controlled delivery of insulin to a patient. Progression in both glucose monitoring and insulin delivery technologies are enabling the delivery of a previously conceptual artificial pancreas system, able to deliver controlled insulin doses, based on sensor outputs to optimise glucose levels. The market for these fully automated diabetes management systems is expected to reach $6.5 billion by 2027.

The report examines diabetes technologies across seven key areas:

  • Sensors for glucose monitoring - The established blood glucose market manufactures over 20 billion test strips annually, however, as is discussed here, several factors are restraining the profitability of the industry and driving technological changes.
  • Beyond blood glucose measurements - Glucose exists in biological fluids other than blood, continuous glucose monitors and wearable devices are gaining traction and seeing large uptake by consumers.
  • Sensors for Ketone monitoring - When blood glucose levels are too high, acidic ketone bodies, the by-product of improper metabolism build up in the blood stream, leading to potentially life threatening complications. The range of available biosensors to measure and quantify ketone levels are reviewed.
  • Smart insulin pens - Start-ups backed by large pharmaceutical companies are adding sensors and connectivity to insulin pens to unlock a range of analytical tools. Several leading start-ups an companies are profiled and their products discussed.
  • Insulin pumps: towards an artificial pancreas - Compared to insulin pens, insulin pumps offer a more controlled rate of hormone delivery. Discussed is the progress whereby combining pump technologies with continuous glucose monitoring platforms is leading to the development of an artificial pancreas device, offering real-time sensor automated insulin delivery in response to changing glucose levels.
  • Sensors for side effects - Covering the diverse utilisation of innovative sensor technologies across novel aspects diabetes care, including; sensors in wearable devices, the ability to monitor other end points such as diabetic neuropathy as well as assessing ulcer development in diabetic patients.
  • Sensors for early diagnosis - Discussing the use of emerging technologies to aid the early detection of diabetes, thereby preventing long hospital stays and other complications.

The report contains 10 year forecasts across all relevant market segments, detailing revenue predictions, and volumes across multiple sensing technologies.

IDTechEx has identified and profiled key players to build a comprehensive picture of the diabetes technology industry. Significant stakeholders have been identified and profiled through primary research and interviews to understand the technology roadmap of diabetes care and to give an insightful, contextual and timely analysis of the industry now and in the future, identifying factors crucial for the triumph of a company in this ever-growing field.

Analyst access from IDTechEx

All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1.1. Diabetes in numbers
  • 1.2. Market segmentation in diabetes care
  • 1.3. Key players and acquisitions- glucose monitoring
  • 1.4. Academic research into glucose monitoring grows every year
  • 1.5. More than 400 billion test strips have been produced
  • 1.6. Ketone monitoring using test strips
  • 1.7. Profitability in the test strip industry is falling
  • 1.8. Blood, sweat & tears: new ways to monitor glucose
  • 1.9. Comparison of sample sites
  • 1.10. Continuous glucose monitors gaining adoption
  • 1.11. Abbott launch rival to CGM systems
  • 1.12. Implanting a sensor under the skin for long term measurement
  • 1.13. New methods in on demand glucose monitoring
  • 1.14. Market forecast: glucose monitoring
  • 1.15. Closed loop artificial pancreas systems represent the next step
  • 1.16. Security is a major issue for closed loop systems
  • 1.17. Smarter insulin delivery informing decisions
  • 1.18. A new $80million investment fund for diabetes
  • 1.19. Report outcomes

2. INTRODUCTION TO DIABETES

  • 2.1. Type 1 diabetes
  • 2.2. Type 2 diabetes
  • 2.3. Gestational diabetes presents dangers for mother and baby
  • 2.4. Differences between type 1 and type 2 diabetes
  • 2.5. Global diabetes figures
  • 2.6. Diabetes treatment costs by region
  • 2.7. Diabetes treatment costs are high
  • 2.8. Diabetes side effects make up 90% of diabetes care costs
  • 2.9. Rising numbers of people with diabetes
  • 2.10. Technologies and functions of diabetes technologies

3. MARKET FORECASTS

  • 3.1. Forecast assumptions
  • 3.2. Market forecast: primary method of glucose monitoring for people with type 1 diabetes
  • 3.3. Market Forecast: Disposable test strips by revenue
  • 3.4. Market Forecast: Disposable test strips by volume
  • 3.5. Market forecast: glucometers by volume
  • 3.6. Market Forecast: Glucometers by revenue
  • 3.7. Market forecast: Wearable glucose sensors by revenue
  • 3.8. Market Forecast: Wearable glucose sensors by volume
  • 3.9. Market forecast: reusable insulin pen devices by volume
  • 3.10. Large market growth in smart pen devices expected
  • 3.11. Market forecast: insulin pump by volume
  • 3.12. Market forecast: insulin pump by revenue
  • 3.13. Sensors within an insulin pump
  • 3.14. Sensors within an insulin pump

4. SENSORS FOR GLUCOSE MONITORING

  • 4.1. Glucose monitoring
  • 4.2. A history of glucose monitoring
  • 4.3. Glucose monitoring strip mechanisms
  • 4.4. Development of the glucose monitoring assay
  • 4.5. Strip monitoring through a glucometer
  • 4.6. Strip manufacture
  • 4.7. Evolution of blood glucose monitors
  • 4.8. Business model for glucose monitoring
  • 4.9. Manufacturers of blood glucose meters
  • 4.10. Electrode deposition: screen printing vs sputtering
  • 4.11. Academic research into glucose sensing
  • 4.12. New materials for biosensors: carbon nanotubes
  • 4.13. New materials for biosensors: quantum dots
  • 4.14. Challenges for printing glucose test strips
  • 4.15. ISO standards are leading to changes in glucose test strip production
  • 4.16. Medicare cuts limiting the glucose strip market
  • 4.17. Key diabetes businesses changing hands
  • 4.18. Drivers and constraints to the disposable test strip industry
  • 4.19. New directions in internet enabled glucometers
  • 4.20. The worlds first smartphone case glucometer
  • 4.21. Finger stick tests as a subscription service
  • 4.22. Large growth in third party diabetes management apps
  • 4.23. Porters five force analysis of disposable test strip industry

5. BEYOND BLOOD GLUCOSE MEASUREMENTS

  • 5.1. Measurements beyond blood
  • 5.2. Measuring glucose through sweat
  • 5.3. Measuring glucose through tears
  • 5.4. Measuring glucose through interstitial fluid
  • 5.5. Measuring glucose through saliva
  • 5.6. Measuring glucose through breath
  • 5.7. Measuring glucose through urine
  • 5.8. Analysis of various glucose sampling sites
  • 5.9. Qualitative glucose monitoring
  • 5.10. Continuous glucose monitoring
  • 5.11. How continuous glucose monitors work
  • 5.12. Continuous vs flash glucose monitoring
  • 5.13. Growing interest in ambulatory glucose monitoring
  • 5.14. Anatomy of a CGM sensor
  • 5.15. CGM sensor manufacture
  • 5.16. Foreign body responses to CGM devices
  • 5.17. Calibration of glucose monitoring devices
  • 5.18. Is continuous glucose monitoring worth the high price?
  • 5.19. Not all glucose measurements are equal
  • 5.20. Factors determining the success of CGM devices
  • 5.21. Key partnerships in emerging glucose monitoring technology
  • 5.22. Abbott Libre
  • 5.23. Abbott Libre glucose detection mechanism
  • 5.24. Components in an Abbott Libre sensor
  • 5.25. Cost of flash glucose monitoring compared to finger stick tests
  • 5.26. New options for short term real time glucose monitoring
  • 5.27. Dexcom
  • 5.28. Dexcom glucose monitoring mechanism
  • 5.29. Medicare provide coverage for Dexcom products
  • 5.30. Cost of glucose monitoring compared to finger stick tests
  • 5.31. Medtronic
  • 5.32. Fitbit & Medtronic announce CGM partnership
  • 5.33. Future miniaturisation of CGM sensors
  • 5.34. Users experience of wearable devices
  • 5.35. FDA gives approval for Dexcom to replace finger stick tests
  • 5.36. Comparison of wearable technologies for glucose monitoring
  • 5.37. Non-invasive glucose monitoring
  • 5.38. Non-invasive glucose sensing by reverse iontophoresis
  • 5.39. Non-invasive glucose monitoring- A first device to market
  • 5.40. Google contact lens- an eye on glucose monitoring
  • 5.41. Problems with a glucose contact lens
  • 5.42. Monitoring glucose through breath analysis
  • 5.43. A sweat sensor that delivers medicine
  • 5.44. iQuick saliva analyser measures glucose from the mouth
  • 5.45. Test strip requirements with newer devices
  • 5.46. Implantable sensors
  • 5.47. Glucose oxidase based implantable sensors
  • 5.48. Fluoresence based implantable sensors
  • 5.49. Failures of the GlucoWatch
  • 5.50. A new generation of glucose monitoring watches
  • 5.51. A non-invasive glucose monitoring wristband?
  • 5.52. A non-invasive monitor has been developed
  • 5.53. Hand held non-invasive monitoring
  • 5.54. Optical testing as the next step for glucose monitoring
  • 5.55. MIT patent Raman based glucose monitoring
  • 5.56. Belgian start-up aims at optical implantable device
  • 5.57. Non invasive optical device being developed
  • 5.58. Single use vs ambulatory monitoring: future directions
  • 5.59. The future for finger stick testing
  • 5.60. Will CGM systems replace test strips?
  • 5.61. The potential for non-invasive testing
  • 5.62. New funding opportunities for diabetes devices

6. SENSORS FOR KETONE MONITORING

  • 6.1. A severe lack of insulin can lead to Diabetic Ketoacidosis
  • 6.2. Ketostix are a historically useful measurement of DKA
  • 6.3. Electrochemical sensors are a more accurate method of ketone monitoring
  • 6.4. Comparison between glucose and ketone test strips
  • 6.5. Will we see continuous ketone monitoring?

7. SENSORS FOR INSULIN PENS

  • 7.1. Insulin pens remain the primary delivery method for patients
  • 7.2. Anatomy Of An Insulin Pen
  • 7.3. At extreme temperatures, insulin dies
  • 7.4. Forgetting a dose can be fatal
  • 7.5. Smart insulin delivery device manufacturers
  • 7.6. First smart pen to market
  • 7.7. Smart pen platform preventing missed doses
  • 7.8. The traditional inulin pen industry diversifying their portfolio
  • 7.9. A Bluetooth connected pen set for US launch
  • 7.10. Applying principles to disposable insulin pens
  • 7.11. Is there room for new insulin pen manufacturers?

8. INSULIN PUMPS: TOWARDS AN ARTIFICIAL PANCREAS

  • 8.1. Insulin pumps offer an automated delivery system
  • 8.2. Insulin pumps currently available
  • 8.3. Towards fully automated insulin delivery
  • 8.4. Insulin pump breakdown
  • 8.5. Sensor functions within a pump
  • 8.6. Insulin pump technology roadmap
  • 8.7. Hacking insulin pumps for autonomous diabetes control
  • 8.8. Closed loop systems are coming
  • 8.9. Modular System Enabling an Artificial Pancreas
  • 8.10. Disposable insulin pumps for type 2 diabetics
  • 8.11. Toward a 'smart' patch that automatically delivers insulin when needed
  • 8.12. Security around insulin pumps is a key issue
  • 8.13. Security risks for medical devices
  • 8.14. Important considerations for device security
  • 8.15. Future markets for insulin pumps

9. SENSORS FOR SIDE EFFECTS

  • 9.1. Treatment of side effects account for 80% of diabetes costs
  • 9.2. Diabetic foot ulcers
  • 9.3. Pressure and Impact Sensors can Detect Foot Problems
  • 9.4. Basic requirements of a diabetic footwear
  • 9.5. Diabetic Insoles
  • 9.6. Sensoria- Diabetic socks
  • 9.7. Diabetic neuropathy is
  • 9.8. Optical measurement of neuropathy
  • 9.9. Sudomotor function as biomarker for neuropathy
  • 9.10. Gait measurement to assess neuropathy

10. SENSORS FOR EARLY DIAGNOSIS

  • 10.1. Diagnosis of diabetes is not a fast process
  • 10.2. Remote Glucose Tolerance Testing is Possible
  • 10.3. E. coli bacteria to change colour in the presence of sugar
  • 10.4. Optical Sensors For Infant Diagnosis

11. REGULATION AND AVAILABILITY OF DIABETES MEDICAL DEVICES

  • 11.1. Austria
  • 11.2. Canada
  • 11.3. France
  • 11.4. Germany
  • 11.5. Ireland
  • 11.6. Netherlands
  • 11.7. Switzerland
  • 11.8. United Kingdom
  • 11.9. USA

12. COMPANY PROFILES

  • 12.1. Companion Medical
  • 12.2. Dexcom
  • 12.3. Dropsens
  • 12.4. Emperra
  • 12.5. Glysens
  • 12.6. Google-Verily
  • 12.7. GSI
  • 12.8. GSK Medical
  • 12.9. Medtronic
  • 12.10. Nanoflex
  • 12.11. PKVitality
  • 12.12. Sensoria
Back to Top